These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29204260)

  • 1. The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.
    Wang TP; Scott JH; Barta SK
    Ther Adv Hematol; 2017 Dec; 8(12):329-344. PubMed ID: 29204260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How we treat mature B-cell neoplasms (indolent B-cell lymphomas).
    Lumish M; Falchi L; Imber BS; Scordo M; von Keudell G; Joffe E
    J Hematol Oncol; 2021 Jan; 14(1):5. PubMed ID: 33407745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
    Tomblyn M
    Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma.
    Arora M; Gowda S; Tuscano J
    Ther Adv Hematol; 2016 Aug; 7(4):209-21. PubMed ID: 27493711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?
    Hamadani M
    Bone Marrow Transplant; 2013 Aug; 48(8):1013-21. PubMed ID: 23000653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas.
    Shah H; Stephens D; Seymour J; Maddocks K
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-18. PubMed ID: 33770460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas.
    Leslie LA
    Curr Treat Options Oncol; 2021 Oct; 22(12):111. PubMed ID: 34694508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular lymphoma: The long and winding road leading to your cure?
    Gordon MJ; Smith MR; Nastoupil LJ
    Blood Rev; 2023 Jan; 57():100992. PubMed ID: 35908982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
    Wagner-Johnston ND; Schuster SJ; deVos S; Salles G; Jurczak WJ; Flowers CR; Viardot A; Flinn IW; Martin P; Xing G; Rajakumaraswamy N; Gopal AK
    Leuk Lymphoma; 2021 May; 62(5):1077-1087. PubMed ID: 33300385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular control of the cell cycle in cancer: biological and clinical aspects.
    Møller MB
    Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in indolent lymphomas.
    Merli M; Ferrario A; Basilico C; Maffioli M; Caramazza D; Appio L; Arcaini L; Passamonti F
    Ther Adv Hematol; 2013 Apr; 4(2):133-48. PubMed ID: 23610620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes.
    van der Jagt R
    Expert Rev Hematol; 2013 Oct; 6(5):525-37. PubMed ID: 24125522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas.
    Artemaki PI; Letsos PA; Zoupa IC; Katsaraki K; Karousi P; Papageorgiou SG; Pappa V; Scorilas A; Kontos CK
    Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33806113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
    Kubuschok B; Trepel M
    Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective.
    Reddy NM; Thieblemont C
    Ann Oncol; 2017 Nov; 28(11):2680-2690. PubMed ID: 29045503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies.
    Smyth E; Cheah CY; Seymour JF
    Cancer Treat Rev; 2023 Feb; 113():102510. PubMed ID: 36634434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
    Weide R; Heymanns J; Gores A; Köppler H
    Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.